Disease relevance of Acetobutolol

• Cutaneous vasculitis due to acebutolol [1].
• Acebutolol-induced pleuropulmonary lupus syndrome [2].
• Hepatic toxicity after acebutolol therapy [3].
• Acebutolol therapy for ventricular arrhythmia. A randomized placebo-controlled double-blind multicenter study [4].
• Effects of acebutolol on myocardial infarct extension: a randomized electrocardiographic, enzymatic and angiographic study [5].

Psychiatry related information on Acetobutolol

• The psychological side effects of acebutolol and atenolol [6].
• Acebutolol did not significantly increase complex reaction time over the placebo value [7].
• Comparison of effect on psychomotor performance of single doses of propranolol and acebutolol [7].
• Patient compliance with therapy was excellent, and there were no side-effects on acebutolol, whereas patients on methyl-dopa reported a significant number of side-effects (p less than 0.002) [8].

High impact information on Acetobutolol

• Antialprenolol rabbit antibodies were fractionated on an acebutolol affinity resin, followed by L-propranolol elution so as to separate a class of binding sites that mimic the beta-adrenergic receptor [9].
• Cardiac and pulmonary effects of acebutolol [10].
• No significant changes in vascular resistance or cardiac output occurred with atenolol or acebutolol [11].
• Effects of acebutolol on chronic stable angina pectoris. A placebo-controlled, double-blind, randomized crossover study [12].
• Acebutolol slowed the heart rate and prolonged the PR interval without affecting the QT interval [13].

Chemical compound and disease context of Acetobutolol

• The effects of 0.5 mg of slow-release (sr) clonidine, 800 mg of acebutolol, and of both drugs combined on blood pressure and the water-salt balance were compared in 10 patients with essential hypertension [14].
• Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension [15].
• Fifteen patients with stable angina pectoris, aged 32 to 79 years (mean = 53), were randomized to propranolol (80 to 160 mg/day) or acebutolol (400 mg/day) treatment groups, and followed for approximately 1 year (mean = 371 days) [16].
• Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction [17].
• Early studies of acute beta-blocking drug therapy, such as metoprolol and acebutolol, in patients with idiopathic dilated cardiomyopathy (IDC) and survivors of acute myocardial infarction were interpreted to have detrimental or, at best, neutral effects on cardiac and clinical hemodynamics [18].

Biological context of Acetobutolol

• These results demonstrate that a rapid decrease in blood pressure can be obtained in patients with essential hypertension treated with acebutolol and that the decrease in blood pressure is related to the initial state of the renin-angiotensin system [19].
• Observations on the pharmacokinetics of acebutolol [20].
• These results demonstrate that in those patients with a hypotensive response to acebutolol, the clinical effect was not related to reduced cardiac output or plasma renin activity, further adding to confusion on the mechanism of the lowering of elevated blood pressure by beta adrenergic blockade [21].
• The effect of nitroglycerin, beta-blockade with acebutolol and isometric stress on incoordinate left ventricular function [22].
• In all groups acebutolol reduced systolic and mean systemic arterial pressure, heart rate, cardiac output, and stroke volume [23].

Anatomical context of Acetobutolol

• The hemodynamic dose-response effects of intravenous acebutolol, a cardioselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity, were evaluated in 12 male subjects with angiographically confirmed coronary artery disease [24].
• Compared with control measurements at rest after saline solution injection, these plasma concentrations of acebutolol resulted in a quadratic reduction in heart rate (maximum delta HR, -4 bpm) and a linear increase in pulmonary artery occluded pressure (maximum delta PAOP, +3 mm Hg) without change in systemic arterial pressure [24].
• Direct effect of acebutolol on force generation in immature and adult myocardium [25].
• The effect of acebutolol on active isometric force generation has been studied in isolated papillary muscle preparations from adult cats and kittens less than 24 h old [25].
• Acebutolol-induced changes in refractoriness and monophastic action potential of the right ventricle of the dog heart in situ [26].

Associations of Acetobutolol with other chemical compounds

• An initial 4-wk, single-blind control phase was followed by two drug treatment periods, each a 3-wk double-blind titration phase (using increasing doses of acebutolol or propranolol), followed by a 5-wk double-blind maintenance phase [27].
• Pulse rate decreased (P less than 0.01) during acebutolol whereas nitrendipine induced a nonsignificant increase [28].
• We report the case of a 24-year-old medical intern who ingested 9.6 g acebutolol, 7.2 g labetalol and 0.625 g trimipramine in an attempted suicide [29].
• There were no differences between the recoveries of skin temperature during pindolol, atenolol, and acebutolol dosing [30].
• The addition of mefruside to nitrendipine or acebutolol produced a further fall of blood pressure in patients not controlled with monotherapy [28].

Gene context of Acetobutolol

• Specific beta 1- and beta 2-adrenoceptor antagonists, acebutolol and butoxamine respectively were used to investigate the involvement of blockade of these receptors in the inhibition of harmaline-induced tremors [31].
• The additive antihypertensive effects of sr-clonidine and acebutolol might be due to the parallel inhibition observed in the renin and sympathetic systems, and to the increase in natriuresis [14].
• Therefore, at an identical beta 1-receptor occupancy, the beta 2-receptor occupancy of acebutolol was larger than that of the other agents [32].
• Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators [33].
• 4. Under these conditions, bisoprolol behaves like a selective beta 1-adrenoceptor antagonist but acebutolol exhibits less beta 1-adrenoceptor selectivity [34].

Analytical, diagnostic and therapeutic context of Acetobutolol

• Dose-dependent acebutolol disposition after oral administration [35].
• It is concluded that: (1) performance criteria are useful predictors of response to beta blockade and (2) acebutolol is a potent antianginal agent when judged by an objective treadmill exercise test [36].
• All patients underwent rest and maximal supine bicycle exercise radionuclide angiography while on placebo and oral acebutolol (400 mg three times a day) [37].
• Twenty eight dogs were randomly allocated to receive acebutolol (3 mg X kg-1 twice daily) or placebo given blindly by mouth for five days; a control group of 14 dogs without any pretreatment underwent the same procedure [38].
• Intravenous injection of acebutolol 2.0 mg.kg-1 increased the times for 50 and 90% repolarisation of the monophasic action potential [26].

References